Skip to main content
TipRanks
Go Ultimate75% OFF

Trevi Therapeutics (TRVI) Stock Price & Analysis

611 Followers

TRVI Stock Chart & Stats

$13.72$0.21(1.55%)
At close: 4:00 PM EST
$12.5$15$17.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$13.27 - $14.20
52-Week Range
$9.82 - $20.22
Previous Close
$13.51
Volume
N/A
Average Volume (3M)
1.96M
Market Cap
$1.96B
Enterprise Value
$1.99B
Total Cash (Recent Filing)
$299.41M
Total Debt (Recent Filing)
$527.00K
Price to Earnings (P/E)
―
Beta
0.52
Next Earnings
Mar 23, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet And Runway

The substantial cash position and stated runway into 2030 provide Trevi with financial capacity to advance multiple clinical programs through important data readouts. Extremely low leverage further reduces near-term financing pressure and supports continued development without relying immediately on debt.

Expanded Patent Protection

Patent protection extending to 2041 can lengthen the period in which successful Haduvio indications may be protected from direct generic competition. Additional dosing and label-related claims also strengthen the company’s ability to build an indication-specific commercial franchise.

Differentiated Clinical Positioning

Supportive regulatory alignment and an apparently uncrowded targeted chronic-cough field improve the strategic opportunity for Haduvio if clinical efficacy is confirmed. The planned expansion into non-IPF-ILD also broadens the development pathway beyond a single patient population.

Bears Say

No Revenue And Widening Losses

Trevi has no commercial revenue base and its losses are increasing as clinical development continues. Until Haduvio is approved and commercialized or partnered, the company lacks operating earnings to fund activities, making future financial performance dependent on successful development milestones.

Accelerating Cash Burn

The worsening operating cash outflow indicates that Trevi is consuming capital more quickly while still pre-revenue. Persistent negative free cash flow creates dependence on external funding over time, potentially reducing financial flexibility and increasing dilution risk if development spending remains elevated.

Future Funding Needs Remain

Although current resources cover the disclosed clinical programs, they do not cover all costs required for commercialization or certain later-stage trials. Those future expenditures could materially extend the funding requirement and create additional execution and capital-allocation pressure before revenue begins.

Trevi Therapeutics News

TRVI FAQ

What was Trevi Therapeutics’s price range in the past 12 months?
Trevi Therapeutics lowest stock price was $9.82 and its highest was $20.22 in the past 12 months.
What is Trevi Therapeutics’s market cap?
Trevi Therapeutics’s market cap is $1.96B.
When is Trevi Therapeutics’s upcoming earnings report date?
Trevi Therapeutics’s next earnings report is estimated for Mar 23, 2027 (not yet confirmed), which is in 122 days.
How were Trevi Therapeutics’s earnings last quarter?
Trevi Therapeutics released its earnings results on Nov 09, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.132 by $0.002.
Is Trevi Therapeutics overvalued?
According to Wall Street analysts Trevi Therapeutics’s price is currently Undervalued.
Does Trevi Therapeutics pay dividends?
Trevi Therapeutics does not currently pay dividends.
What is Trevi Therapeutics’s EPS estimate?
Trevi Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Trevi Therapeutics have?
Trevi Therapeutics has 142,559,400 shares outstanding.
What happened to Trevi Therapeutics’s price movement after its last earnings report?
Trevi Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.132. Following the earnings report the stock price went down -2.613%.
Which hedge fund is a major shareholder of Trevi Therapeutics?
Hedge funds hold Trevi Therapeutics shares: the largest hedge-fund position in Trevi Therapeutics is 72,326,626 shares, and hedge funds increased their holdings by 2.0M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology